The COVID-19 Drug Discovery Consortium (DDC) is an international team of leading computational scientists, medicinal chemists, biochemists, and virologists working to rapidly identify drug-like molecules that inhibit SARS-CoV-19 replication. We are leveraging on some of the world’s most advanced supercomputer resources to screen billions of small molecules against all the major non-structural proteins of SARS-CoV-19. We are going to test the tightest binding drug-like molecules for antiviral activity using novel SARS-CoV-19 replication assays performed in high containment facilities. Following these assays, the most potent antiviral compounds will transition to IND-enabling GMP manufacturing and GLP safety/toxicity studies in preparation for First-in-Human clinical studies.
- Suman Sirimulla, University of Texas at El Paso
- Stanley Watowich, University of Texas Medical Branch
- Francisco J. Enguita, University of Lisbon
- Mark White, University of Texas Medical Branch
- Xiaodong Cheng, MD Anderson Cancer center
- Joe Allen, Texas Advanced Computing Center, UT Austin
- Ritu Arora, Texas Advanced Computing Center, UT Austin
- Amit Gupta, Texas Medical Center Innovation Institute, Houston
- Adrian Varela-Alvarez, University of Texas at El Paso
- Jin Wang, Baylor College of Medicine
- JoAnne Babula, Ridgeline Therapeutics
- Josh T Beckham, University of Texas at Austin
- Lisheng Deng, Baylor College of Medicine
- Rajan Chaudhari, MD Anderson Cancer Center
- Rodrigo Ochoa, University of Antioquia Colombia
- Sita Sirisha Madugula, COVID19 Drug Discovery Consortium
- Yun Lyna Luo, Western University of Health Sciences
- Enamine
- Texas A&M Institute for Biosciences & Technology (Houston, Tx)
- Boston University’s National Emerging Infectious Diseases Laboratories(NEIDL)